PRP Tube Anticoagulants Explained — ACD vs Sodium Citrate vs Heparin

Introduction

The anticoagulant in a PRP tube does more than prevent clotting. It establishes the biochemical environment in which platelets are concentrated, determines whether ionized calcium is available for post-preparation activation, and influences the stability and bioactivity of platelet-derived growth factors.

Three anticoagulant systems dominate clinical PRP practice: ACD-A (acid citrate dextrose), sodium citrate, and sodium heparin. While all three prevent clot formation during blood collection and centrifugation, they differ in their mechanism of action, effect on platelet physiology, and suitability for specific clinical applications.

This article provides a detailed biochemical and clinical comparison of the three anticoagulant systems, with guidance on selecting the appropriate system for your protocol.

2. ACD-A (Acid Citrate Dextrose Solution A)

Composition

ACD-A contains three components:

• Citric acid — lowers pH to approximately 5.0, optimizing anticoagulant stability
• Sodium citrate — chelates ionized calcium (Ca²⁺), interrupting the coagulation cascade at multiple points
• Dextrose — serves as a metabolic substrate for platelets, supporting ATP production and maintaining platelet viability during the preparation period

Mechanism of Anticoagulation

Citrate ions bind free ionized calcium in the blood, forming soluble calcium-citrate complexes. Since calcium is an essential cofactor at multiple steps in the coagulation cascade — including the activation of factor X, prothrombin conversion to thrombin, and fibrin polymerization — its depletion effectively suspends coagulation.

The anticoagulation is reversible: if calcium is reintroduced (e.g., via calcium chloride addition or exposure to tissue calcium at the injection site), the cascade resumes and platelets activate.

Clinical Profile

• Platelet viability: ACD-A preserves platelet metabolic activity. The dextrose component serves as an energy source for platelet ATP production during the preparation period
• Growth factor preservation: ACD-A does not chemically interfere with PDGF, TGF-β, VEGF, EGF, FGF, or IGF-1. This is a key reason for its widespread adoption in aesthetic and regenerative PRP applications
• Plasma pH: The citric acid component produces a mildly acidic plasma environment (pH ~6.5–7.0) that stabilizes platelets in a quiescent state
• Clinical precedent: ACD-A is the most extensively studied anticoagulant in published PRP literature across aesthetic, orthopedic, and hair restoration applications

3. Sodium Citrate (3.2% / 3.8%)

Composition

Sodium citrate solution — typically at 3.2% (0.109 M) or 3.8% (0.129 M) concentration — without dextrose or pH adjustment.

Mechanism of Anticoagulation

Identical mechanism to ACD-A: citrate chelates ionized calcium. The difference is formulation simplicity — sodium citrate alone provides anticoagulation but does not provide the metabolic substrate (dextrose) or pH optimization (citric acid) that ACD-A offers.

Clinical Profile

• Platelet viability: Adequate for short preparation times, but platelets may be less metabolically supported than in ACD-A due to the absence of dextrose
• Growth factor preservation: Preserved, as with ACD — citrate chelation does not directly affect growth factor bioactivity
• Plasma pH: Less acidic than ACD-A-prepared PRP, which may be relevant in protocols where pH-sensitive activation kinetics are a consideration
• Clinical precedent: Used in some PRP protocols, particularly where the practitioner prefers a simpler formulation or where ACD-A is not available. Less extensively studied in head-to-head comparisons with ACD-A in PRP literature

Practical Distinction

Sodium citrate tubes — recognizable as the standard light-blue-top coagulation testing tubes — should not be confused with PRP-specific sodium citrate tubes. Standard blue-top tubes are in vitro diagnostic devices and are not manufactured, labeled, or validated for preparation of injectable PRP. If sodium citrate PRP is desired, use only tubes specifically manufactured and CE-marked as PRP medical devices.

4. Sodium Heparin

Composition

Heparin is a sulfated glycosaminoglycan, typically sourced from porcine intestinal mucosa. Pharmaceutical-grade sodium heparin is used in PRP tubes at validated concentrations.

Mechanism of Anticoagulation

Heparin acts fundamentally differently from citrate-based anticoagulants. Rather than depleting calcium, heparin binds to and potentiates antithrombin III — a naturally occurring plasma protein that inhibits thrombin (factor IIa) and factor Xa. The coagulation cascade is suspended not because calcium is unavailable, but because the central enzymatic steps of coagulation are inhibited.

Critically, heparin does not deplete ionized calcium. Calcium remains present and available in the PRP preparation. This has two clinical implications:

1. Endogenous activation: When heparin-PRP is injected into tissue, the calcium naturally present in the preparation can participate in platelet activation and the early stages of the coagulation/fibrin formation cascade without the need for exogenous calcium supplementation
2. No recalcification step needed: Unlike citrate-PRP, where calcium chloride may be added to reverse anticoagulation before application, heparin-PRP requires no recalcification

Clinical Profile

• Platelet viability: Preserved. Heparin does not directly affect platelet metabolism
• Growth factor preservation: Generally preserved, though some evidence suggests heparin may bind certain growth factors (particularly FGF family members) through its sulfated glycosaminoglycan structure. The clinical significance of this interaction is not well-established
• Calcium availability: Full calcium availability maintained — a distinguishing feature from citrate systems
• Clinical precedent: More limited than ACD-A in PRP-specific literature, though heparin is extensively used in other blood product preparations
• Patient considerations: A small subset of patients may have heparin sensitivity or heparin-induced thrombocytopenia (HIT). While the exposure from a PRP preparation is autologous and local, a patient history should be reviewed

5. Comparison Table

Parameter	ACD-A	Sodium Citrate	Sodium Heparin
Anticoagulation mechanism	Calcium chelation	Calcium chelation	Antithrombin III potentiation
Calcium post-preparation	Depleted	Depleted	Preserved
Metabolic substrate	Dextrose present	None	None
Plasma pH	Mildly acidic (~6.5–7.0)	Near physiologic (~7.2–7.4)	Near physiologic
Growth factor interference	None documented	None documented	Possible FGF binding (uncertain significance)
Recalcification required	Yes, if exogenous activation desired	Yes	No
Clinical experience (PRP literature)	Extensive	Limited	Moderate (more in orthopedics)
Typical clinical use	Aesthetics, hair, orthopedics	Select protocols	Orthopedics, sports medicine
Gel separator compatibility	Standard	Standard	Standard
Regulatory status (tube)	CE-marked medical device	CE-marked medical device (if PRP-specific)	CE-marked medical device

6. EDTA — Why It Should Not Be Used for PRP

EDTA (ethylenediaminetetraacetic acid) is the anticoagulant in standard lavender/purple-top blood collection tubes used for complete blood count (CBC) testing. While it is a potent anticoagulant, it is not appropriate for PRP preparation for three reasons:

1. Irreversible platelet effects: EDTA chelates calcium so aggressively that it causes irreversible conformational changes in platelet membrane glycoproteins, including the GPIIb/IIIa receptor required for platelet aggregation and activation. EDTA-exposed platelets are functionally compromised
2. Regulatory classification: EDTA tubes are in vitro diagnostic (IVD) devices — they are designed, manufactured, and validated for laboratory analysis of blood samples, not for preparation of therapeutic products intended for injection
3. No CE marking for therapeutic use: EDTA tubes do not carry CE marking as medical devices for PRP preparation. Using an IVD device for therapeutic preparation is off-label use and introduces regulatory risk

7. How to Choose: Decision Framework

``` Which clinical application? ├─ Aesthetic / Hair / General → ACD-A (most evidence, growth factor compatible) ├─ Orthopedic — tendon → ACD-A or Heparin (provider preference) ├─ Orthopedic — intra-articular → ACD-A (LP-PRP compatible) └─ Protocol requires endogenous calcium → Heparin

Verify: ├─ Tube is CE-marked as a medical device (not IVD) ├─ ISO 13485 manufacturer certification ├─ Anticoagulant type matches protocol specification └─ Batch-specific CoA available ```

Anticoagulant choice is one part of tube selection — see how it fits with gel technology and sizing in the complete PRP tubes guide. For a ready clinical configuration, our 10 ml ACD-A + gel tube is the standard starting point.

Frequently Asked Questions

Is ACD-A better than sodium citrate for PRP?

ACD-A is more widely used and better characterized in PRP literature. The dextrose component provides metabolic support for platelets, and the citric acid produces a mildly acidic pH that stabilizes platelets. Sodium citrate provides effective anticoagulation but lacks these additional features. For clinical PRP, ACD-A is the default choice unless a specific protocol reason dictates otherwise.

Can I use a standard light-blue-top sodium citrate tube for PRP?

No. Standard light-blue-top tubes are in vitro diagnostic devices for coagulation testing (PT, aPTT). They are not manufactured, labeled, CE-marked, or validated for preparation of injectable PRP. Use only PRP-specific CE-marked medical device tubes.

Why would anyone use heparin instead of ACD for PRP?

The primary reason is calcium preservation. Heparin anticoagulation leaves ionized calcium available in the preparation, which some clinicians consider advantageous for natural platelet activation upon injection without the need for exogenous calcium chloride. Heparin may also be selected for protocols where the mildly acidic pH of ACD-PRP is undesirable.

What happens if the wrong anticoagulant is used?

Clinical consequences depend on the mismatch. Using an IVD tube for PRP preparation (EDTA or diagnostic citrate) introduces platelet dysfunction and regulatory non-compliance. Using a heparin tube for a protocol designed for ACD-PRP may produce acceptable PRP but introduces undocumented preparation variability. Always match the tube to the documented protocol.

Disclaimer: This article provides general technical information based on published literature and clinical practice patterns. It does not constitute medical advice. Tube and anticoagulant selection should be based on your specific clinical protocol, product Instructions for Use, and regulatory requirements.

For CE-marked PRP tubes with ACD-A, sodium heparin, and other anticoagulant configurations, browse the PRP tubes collection. For protocol-specific product guidance, contact our team.